Literature DB >> 20472599

A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment.

Hilde Berner Hammer1, Margareth Sveinsson, Anne Katrine Kongtorp, Tore K Kvien.   

Abstract

OBJECTIVES: To examine associations between ultrasonography (US) assessments (B-mode (BM) and power Doppler (PD)) of a large number of joints and traditional assessments of disease activity, and to examine the sensitivity to change of the US scores and clinical measures in patients with rheumatoid arthritis (RA).
METHODS: Twenty patients with RA initiating adalimumab treatment were examined at baseline and after 1, 3, 6 and 12 months with US (BM and PD) using an Outcome Measures in Rheumatoid Arthritis Clinical Trial semiquantitative scoring (0-3) of 78 joints as well as assessment of clinical and laboratory variables with calculation of composite indexes.
RESULTS: The US scores were associated with composite scores as well as clinical and laboratory variables (r=0.41-0.84, p<0.05-0.001 at 12-months' follow-up). Compared with clinical assessments, US detected higher numbers of inflamed joints. The US scores decreased after 1 and 3 months (p<0.005) and PD showed the highest percentage improvement. Both BM and PD had high standardised response means throughout the study (-0.83 to -1.27), of similar magnitude to composite indexes, but higher than the clinical and laboratory variables.
CONCLUSIONS: The comprehensive US assessments were associated with clinical and laboratory variables of disease activity and were highly sensitive to change during treatment with biological agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472599     DOI: 10.1136/ard.2009.126995

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

Review 1.  Ultrasonography in inflammatory rheumatic disease: an overview.

Authors:  Michael Schirmer; Christina Duftner; Wolfgang A Schmidt; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2011-07-12       Impact factor: 20.543

2.  Validation of power Doppler versus contrast-enhanced magnetic resonance imaging quantification of joint inflammation in murine inflammatory arthritis.

Authors:  Echoe M Bouta; Peony D Banik; Ronald W Wood; Homaira Rahimi; Christopher T Ritchlin; Ralf G Thiele; Edward M Schwarz
Journal:  J Bone Miner Res       Date:  2015-04       Impact factor: 6.741

Review 3.  Role of ultrasound in managing rheumatoid arthritis.

Authors:  Hilde Berner Hammer; Lene Terslev
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

Review 4.  Assessing rheumatoid arthritis disease activity with ultrasound.

Authors:  Rafael Mendonça da Silva Chakr; José Alexandre Mendonça; Claiton Viegas Brenol; Ricardo Machado Xavier; João Carlos Tavares Brenol
Journal:  Clin Rheumatol       Date:  2013-05-23       Impact factor: 2.980

5.  The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab.

Authors:  Hilde Berner Hammer; Magne K Fagerhol; Tale Norbye Wien; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2011-10-26       Impact factor: 5.156

6.  Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis.

Authors:  Hilde Berner Hammer; Tore K Kvien
Journal:  Arthritis Res Ther       Date:  2011-05-27       Impact factor: 5.156

7.  Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study.

Authors:  M Teoli; A Zangrilli; M S Chimenti; M Talamonti; M Bavetta; D Graceffa; R Perricone; S Chimenti
Journal:  Clin Dev Immunol       Date:  2012-05-09

8.  Gray-scale and color duplex Doppler ultrasound of hand joints in the evaluation of disease activity and treatment in rheumatoid arthritis.

Authors:  Gordana Ivanac; Jadranka Morović-Vergles; Boris Brkljačić
Journal:  Croat Med J       Date:  2015-06       Impact factor: 1.351

9.  The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.

Authors:  Sella Aarrestad Provan; Inger Jorid Berg; Hilde Berner Hammer; Alexander Mathiessen; Tore Kristian Kvien; Anne Grete Semb
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

10.  Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study.

Authors:  Carlomaurizio Montecucco; Monica Todoerti; Garifallia Sakellariou; Carlo Alberto Scirè; Roberto Caporali
Journal:  Arthritis Res Ther       Date:  2012-05-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.